The 24th CPHI China concluded successfully at the Shanghai New International Expo Center on June 16–18, 2026. As the pharmaceutical industry’s annual flagship event, this edition gathered over 3,700 leading pharmaceutical enterprises, core raw material suppliers and supply chain service providers worldwide, attracting high-end professional buyers, R&D leaders and industry decision-makers from more than 180 countries and regions across Europe, the Americas, the Asia-Pacific, the Middle East and beyond. With record-breaking scale, professional depth and global influence, this year’s expo further cemented its status as a key bellwether for the worldwide pharmaceutical sector.

Space Peptides (Taizhou) Pharmaceutical Co., Ltd., a rising powerhouse in the peptide industry, drew extensive attention from domestic and overseas clients at CPHI 2026. The company showcased its AI-empowered innovative peptide pipeline, cutting-edge synthetic technology solutions and full-spectrum, one-stop peptide CRDMO services. Drawing on reliable product quality and a standardized professional service system, Space Peptides held in-depth technical exchanges and business discussions with industry partners from around the world.

Core Theme: “Innovation-Driven, Intelligent & Quality Manufacturing”

Centered on this strategic theme, Space Peptides built a futuristic, immersive brand booth that showcased its core strengths in AI-enabled novel peptide drug R&D and AI-backed intelligent peptide manufacturing.

Over the three days, the booth saw strong, steady foot traffic. Industry partners, research institutions and decision-makers from core global markets — including Europe, the United States, Japan, South Korea, Southeast Asia, the Middle East and Latin America — visited in succession, expressing strong recognition of Space Peptides’ quality management systems, technical capabilities and global production capacity.

Through dynamic digital screens, a VR virtual peptide molecular library experience, physical product displays and full-process technical demonstrations, the booth brought to life Space Peptides’ complete industrial loop — from early-stage drug discovery to commercial-scale manufacturing. Two core competitive advantages stood out:

I. A new paradigm for AI-empowered novel peptide drug R&D

Built on years of independent drug research and development, the company has established a leading AI peptide drug development platform in China, covering seven core therapeutic areas — including oncology, metabolism and endocrinology — with nearly 60 in-house pipeline projects under development.

Space Peptides delivers end-to-end CRDMO services spanning AI-driven molecular screening, precise peptide synthesis, pharmacology & toxicology studies and large-scale commercial manufacturing. These integrated services dramatically shorten the R&D cycle for innovative peptide therapeutics, systematically lower development costs and risks for global pharmaceutical firms, and redefine the efficiency frontier of peptide drug development.

II. An intelligent, GMP-standard peptide manufacturing base

Space Peptides operates a self-built, fully integrated GMP-standard intelligent CDMO facility for peptide API production, spanning roughly 8 hectares (120 mu / ~20 acres). Phase I features 8 standardized production lines enabling flexible, parallel manufacturing of multiple products, with full-gradient capacity from gram-level lab samples to ton-scale commercial supply.

Leveraging intelligent manufacturing and lean quality management systems, Space Peptides provides stable, efficient and dependable supply chain support for clients worldwide.

Global Partnerships Taking Shape

During the exhibition, global strategic partners held exclusive, high-level one-on-one discussions with Space Peptides’ core management team on key topics including deep supply chain collaboration, custom peptide manufacturing, overseas technology transfer and joint new drug development. Multiple major strategic letters of intent were signed — injecting strong momentum into the company’s global expansion and marking a new milestone in its international development.

A Full-Lifecycle Team Earning Global Trust

The outstanding reception at this year’s CPHI reflects the coordinated effort and professional expertise of Space Peptides’ cross-functional team. From strategic planning, brand visual design and meticulous material preparation to on-site business reception and in-depth technical consultations, teams across business & marketing, drug R&D, quality compliance and production technology worked seamlessly together. Drawing on deep industry expertise and a customer-first philosophy, they delivered a high-caliber, immersive technical exchange for every visitor — further strengthening the company’s brand reputation and credibility in international markets.

Looking Ahead: Continuous Innovation, Boundless Global Collaboration

The three-day CPHI China 2026 has concluded, but Space Peptides’ journey of peptide innovation and global expansion continues.

Moving forward, the company will stay committed to its core principles — technological innovation, quality first, and customer focus. It will continue to advance its AI peptide drug R&D platform, expand capacity at its intelligent manufacturing base, refine its global compliance service system, and deepen full-industry-chain partnerships at home and abroad — working hand in hand with pharmaceutical partners worldwide to advance the high-quality development of the global biopharmaceutical industry.